%A %T Expression of HBME-1, Galectin-3 and CD44v6 in Follicular Thyroid Carcinoma and Atypical Adenoma %0 Journal Article %D 2010 %J Science & Technology Review %R %P 37-40 %V 28 %N 07 %U {http://www.kjdb.org/CN/abstract/article_2260.shtml} %8 2010-04-13 %X his paper studies the immunohistochemical expressions of HBME-1, Galectin-3 and CD44v6 in Follicular Thyroid Carcinoma(FTC) and Atypical Thyroid Adenoma(ATA), in order to find out useful markers for their clinicopathological diagnosis and pathogenesis. SP immunohistochemical technique was applied to detect the expressions of HBME-1, Galectin-3 and CD44v6 in 37 FTC and 18 ATA. 10 cases of oncocytic thyroid adenoma(OTA), 8 cases of general follicular adenoma(FTA), and 7 cases of papillar thyroid carcinoma(PTC) were considered, together with 5 cases of normal thyroid from autopsy as the control group. Results show that the expressions of HBME-1, Galectin-3 and CD44v6 were 70.3%, 64.9%, 62.2% in FTC, 66.7%,61.1%,61.1% in ATA, respectively. These three markers do not have difference of statistical significance in FTC and ATA( χ2 and P values were 0.074 and 0.786, 0.094 and 0.759, 0.245 and 0.62, respectively). In the control group, the expressions of HBME-1, Galectin-3 and CD44v6 were all positive in OTA, 3/8, 6/8, 4/8 in FTA, 7/7, 6/7, 7/7 in PTC and negative in 5 normal thyroid. It is concluded that there is no statistical significance of HBME-1, Galectin-3 and CD44v6 in the diagnosis and differential diagnosis of FTC and ATA, and it should pay more attention to follow up these three markers. More studies are required on the diagnosis and differential diagnosis of FTC and ATA